Intimation under Regulation 30 of SEBI (LODR) Regulation, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals informed the stock exchange that shareholders approved three appointments at the 38th Annual General Meeting held on September 30, 2025 via video conferencing. Two new Non-Executive Independent Directors — Ms. Sonal Dharmin Desai (a Company Secretary with corporate law expertise) and Mr. Anshu Agarwal (a Chartered Accountant and US CPA working at Fust Charles LLP) — were confirmed for 5-year terms after initially being appointed as Additional Directors on July 30, 2025. Additionally, Ms. Kala Agarwal, a Practicing Company Secretary, was appointed as Secretarial Auditor for 5 consecutive financial years (FY 2025-26 to FY 2029-30). Neither of the new independent directors is related to any existing board members.
These are routine governance appointments adding independent oversight and strengthening the company's compliance and audit framework. No material financial impact on shareholders is expected from this disclosure.